ITI MF

CATEGORY OF SCHEME	Sectoral/Thematic
INVESTMENT OBJECTIVE	The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Inception Date (Date of Allotment):	08-Nov-21
Benchmark:	Nifty Healthcare TRI
Minimum Application Amount:	Rs.5,000/- and in multiples of Rs. 1/- thereafter
Load Structure:	Entry Load: Nil Exit Load: 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units · Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.
Total Expense Ratio (TER):	Including Additional Expenses and Goods and Service Tax on Management Fees Regular Plan: 2.34% Direct Plan: 0.43%
Fund Manager	Mr. Rohan Korde (Since 08-Nov-21) Total Experience: 19 years Mr. Dhimant Shah (Since 01 December 2022) Total Experience : 26 years

AUM (in Rs. Cr):	156.92
AAUM (in Rs. Cr):	156.68
% of top 5 holdings:	38.83%
% of top 10 holdings:	57.78%
No. of scrips:	36

Standard Deviation^:	NA
Beta^:	NA
*Sharpe Ratio^:**	NA
Average P/B	7.50
Average P/E	48.75
Portfolio Beta	0.75
Portfolio Turnover Ratio	0.60
^Scheme has not completed 3 years hence NA * Risk free rate:6.80 (Source: FIMMDA MIBOR)

	Regular Plan (in Rs.)	Direct Plan (in Rs.)
Growth:	13.4650	14.1433
IDCW:	13.4650	14.1433

Name of the Instrument	% to NAV	% to NAV Derivatives
Equity & Equity Related Total	95.35
Chemicals	3.71
Archean Chemical Industries Limited	1.83
Vishnu Chemicals Limited	1.22
Astec LifeSciences Limited	0.67
Healthcare	91.63
Sun Pharmaceutical Industries Limited	16.63
Lupin Limited	6.15
Dr. Reddy's Laboratories Limited	5.74
Max Healthcare Institute Limited	5.43
Mankind Pharma Limited	4.88
Suven Pharmaceuticals Limited	4.33
Apollo Hospitals Enterprise Limited	3.90
Divi's Laboratories Limited	3.72
Zydus Lifesciences Limited	3.69
Cipla Limited	3.32
Laurus Labs Limited	2.95
Aurobindo Pharma Limited	2.35
Syngene International Limited	2.23
Alembic Pharmaceuticals Limited	2.13
Orchid Pharma Limited	2.00
FDC Limited	1.94
JB Chemicals & Pharmaceuticals Limited	1.87
Piramal Pharma Limited	1.74
IPCA Laboratories Limited	1.45
Vijaya Diagnostic Centre Limited	1.44
Healthcare Global Enterprises Limited	1.36
Sun Pharma Advanced Research Company Limited	1.36
Ajanta Pharma Limited	1.28
Caplin Point Laboratories Limited	1.20
GlaxoSmithKline Pharmaceuticals Limited	1.13
Rainbow Childrens Medicare Limited	1.11
Sanofi India Limited	1.07
Abbott India Limited	1.06
Shilpa Medicare Limited	0.98
Fortis Healthcare Limited	0.93
Jupiter Life Line Hospitals Limited	0.92
Sequent Scientific Limited	0.85
Strides Pharma Science Limited	0.49
Short Term Debt & Net Current Assets	4.65

Top Ten Holdings

Period	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Benchmark (Rs)	Fund (Rs)	Additional Benchmark Returns (Rs)
Regular - Growth
Last 1 Year	52.7%	60.3%	28.4%	15,290	16,048	12,849
Since Inception	13.7%	16.0%	10.1%	13,465	14,085	12,488
Direct - Growth
Last 1 Year	55.9%	60.3%	28.4%	15,610	16,048	12,849
Since Inception	16.2%	16.0%	10.1%	14,143	14,085	12,488

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. The performance data for 3 years period has not been provided, since scheme is in existence for less than 3 years. In case, the start / end date of the concerned period is a non-business date (NBD), the NAV of the previous date is considered for computation of returns. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Rohan Korde (Managing since 08-Nov-21) and Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021). Face Value per unit: Rs. 10. ITI Pharma & Healthcare Fund NAV as on Feb 29, 2024: Rs. 13.4650 (Regular Growth Option), Rs. 14.1433 (Direct Growth Option)

Period	Amount Invested	Fund Value ()	Fund Returns (%)	Benchmark Value ()	Benchmark Returns (%)	Additional Benchmark Value ()	Additional Benchmark Returns (%)
Regular - Growth
Last 1 Year	1,20,000	1,54,101	56.82%	1,58,863	65.31%	1,37,805	28.73%
Since Inception	2,80,000	3,82,608	28.15%	3,94,870	31.25%	3,44,000	18.05%
Direct - Growth
Last 1 Year	1,20,000	1,55,856	59.94%	1,58,863	65.31%	1,37,805	28.73%
Since Inception	2,80,000	3,92,553	30.66%	3,94,870	31.25%	3,44,000	18.05%

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).